STAAR Surgical Forecasts Q1 Net Sales Above $90M
Summary
STAAR Surgical announced preliminary first-quarter net sales are expected to exceed $90 million. This positive guidance comes after a challenging fiscal year 2025, where the company reported a significant 23.7% drop in net sales and a widened net loss. The projected Q1 performance suggests a potential stabilization or early turnaround in the company's operational trajectory, which could be a significant positive catalyst for the stock. Traders will closely monitor the official Q1 earnings release for confirmation of these figures and any updated full-year outlook.
At the time of this announcement, STAA was trading at $24.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $14.69 to $30.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.